{"nctId":"NCT02673489","briefTitle":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","startDateStruct":{"date":"2016-03-15","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":106,"armGroups":[{"label":"Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)","type":"EXPERIMENTAL","interventionNames":["Drug: DCV","Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"DCV","otherNames":[]},{"name":"SOF","otherNames":[]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Genotype 3 HCV\n* HCV RNA â‰¥10000 IU (International Unit)/mL\n* Compensated Liver Cirrhosis\n* BMI 18-40 kg/m2\n* Previously treated for HCV or never treated for HCV\n\nExclusion Criteria:\n\n* Infection with HCV other than Genotype 3. Mixed infection of any genotype\n* Evidence of decompensated liver disease\n* Previous exposure to NS5A inhibitors\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR12)","description":"SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve SVR12 in the Presence and Absence of Baseline NS5A (Non-structural Protein 5A) Resistance-associated Polymorphisms","description":"SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Achieve HCV RNA < LLOQ, TD or TND Through Follow up Week 24","description":"HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria. SVR12 is based on Next Value Carried Backwards approach.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Achieve HCV RNA < LLOQ, TND Through Follow up Week 24","description":"HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up.\n\nModified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":78},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Anaemia"]}}}